Panoptes is a privately held clinical stage biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria.
Since its foundation in year 2013, Panoptes has successfully developed two drug products, PaniJect and PaniDrop, which are currently investigated in clinical studies to treat severe eye diseases with high unmet medical need.
Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products.
Panoptes’ aim is to generate future growth by achieving major development milestones and by entering into partnerships with leading pharmaceutical companies. We believe the combination of our technology and cost-efficient development strategy will help ensure a rapid and more predictable path to commercialization and has the potential of making needed therapies available to more patients.